MorphoSys AG

MOR

DE0006632003

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 09:06:10 17/07/2024 pm IST			After market 12:55:34 am
67.75 ^EUR	0.00%		67.38	-0.55%

12:42pm	Oxford Biomedica Names New Finance Chief	MT
11:52am	K3 Business sees interim revenue decline	AN

MORPHOSYS : JP Morgan downgrades from Neutral to Sell rating

January 03, 2023 at 01:25 pm IST

JP Morgan degrades the stock. Initially neutral, the broker is now advising to sell. The target price is decreased from EUR 18 to EUR 11.

Latest news about MorphoSys AG

Oxford Biomedica Names New Finance Chief	04:12pm	MT
K3 Business sees interim revenue decline	03:22pm	AN
MorphoSys Informs Nasdaq Stock Market of Delisting Plans After Novartis Merger	15/07	MT
Novartis Seeks Squeeze Out Approval at MorphoSys AGM	12/07	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	26/06	MT
INDEX-MONITOR: Tui, Rational and Traton in the MDax - Douglas moves up to the SDax	24/06	DP
MorphoSys AG(XTRA:MOR) dropped from Germany MDAX Index (Performance)	24/06	CI
MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX (Total Return) Index	24/06	CI
MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX Index (Price Return)	24/06	CI
Dpa-AFX Overview: COMPANIES from 20/06/2024 - 15:15	20/06	DP
Novartis: towards the filing of a buyout offer for MorphoSys	20/06	CF
MorphoSys Set to Delist Following Acquisition by Novartis	20/06	MT
MorphoSys Inks Delisting Agreement After Takeover by Novartis	20/06	MT
Biotech company Morphosys will soon disappear from the stock exchange	20/06	RE
MorphoSys to Leave Deutsche Börse’s MDAX, TecDAX Indices	19/06	MT
MorphoSys AG(XTRA:MOR) dropped from S&P Global BMI Index	10/06	CI
MorphoSys AG Announces Board Changes	07/06	CI
MorphoSys AG Appoints Arkadius Pichota as Chief Executive Officer	07/06	CI
MorphoSys AG Appoints Lukas Gilgen as CFO	07/06	CI
Three newcomers to the MDax - Rational, TUI and Traton move up	06/06	RE
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	04/06	MT
SMA Solar and Morphosys are about to leave the MDax	03/06	RE
Novartis data42 AG completed the acquisition of MorphoSys AG from group of shareholders.	30/05	CI
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading	20/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	17/05	MT

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Call

More about the company

Income Statement Evolution

More financial data

Ratings for MorphoSys AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

67.75 EUR

Average target price

58.71 EUR

Spread / Average Target

-13.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MORPHOSYS AG	+99.26%	2.78B
MODERNA, INC.	+23.70%	47.96B
IQVIA HOLDINGS INC.	+0.19%	42.45B
LONZA GROUP AG	+43.96%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+26.26%	31.6B
ICON PUBLIC LIMITED COMPANY	+19.63%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+51.16%	14.56B
MEDPACE HOLDINGS, INC.	+44.20%	14.14B
BIO-TECHNE CORPORATION	+1.89%	12.58B

Other Biotechnology & Medical Research

MorphoSys AG

Equities

MOR

DE0006632003

Biotechnology & Medical Research

MORPHOSYS : JP Morgan downgrades from Neutral to Sell rating

Latest news about MorphoSys AG

Chart MorphoSys AG

Company Profile

Income Statement Evolution

Ratings for MorphoSys AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research